Alle Storys
Folgen
Keine Story von LAB International Inc mehr verpassen.

LAB International Inc

LAB International Acquires Scantox

Laval, Canada (ots/PRNewswire)

- Danish Contract Research Organization Will Help Double LAB
Research's  Revenues
LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA:
LD9.DE), an integrated drug development company with a focus on
inhalation delivery, today announced it has acquired all shares of
Scantox, Biologisk Laboratorium A/S (Denmark), the leading
Scandinavian, non- clinical contract research organization, for a
total cash consideration of 28 million Danish Kroner ("Dk") or
approximately CDN$6.1 million. Approximately ninety per cent (90%) of
the purchase price will be paid on closing, with the remaining
portion payable by March 31, 2006 subject to post- closing
adjustments.
"We are extremely pleased to welcome Scantox's organization and
staff to the LAB group of companies. Scantox's total customer
satisfaction philosophy, reflected through reliable, flexible and
punctual service, matches perfectly with LAB's core business values,"
said Leigh Berryman, President of LAB Research.
"This acquisition will help us to more than double our current
revenues in 2005 and expand our product offering to our existing
clients," said Dr. Halvor Jaeger, CEO of LAB. "We have a proven track
record for successfully integrating acquisitions and ensuring
synergies are achieved. With the addition of Scantox, our services
business will be large enough to position us closer to being
self-reliant in funding our internal drug development programs."
LAB Research will now be operating contract research facilities in
Denmark, Hungary, United States and Canada with a total capacity
approaching 300,000 square feet and 375 employees.
Scantox is the principal GLP-compliant, non-clinical Contract
Research Organization (CRO) in Scandinavia. Founded in 1977, Scantox
employs 135 people at its state-of-the-art 75,000 sq. ft. facilities
located in Denmark. Scantox' revenues will be consolidated into LAB's
revenues starting at the date of acquisition. Scantox's non-audited
revenues and EBITDA for the 2004 calendar year are estimated at 92
Million Dk (CDN$22 million), and 19.5 million Dk (CDN$4.2 million),
respectively.
In the past twelve months ended September 30, 2004, LAB Research
generated more than CDN$22 million in revenue and CDN$5.4 million in
EBITDA.
About LAB International
LAB International (LAB Pharma and LAB Research) is an integrated
drug development company. LAB Pharma is focused on the growing
multi-billion dollar inhalation market. Its lead product, for the
treatment of breakthrough cancer pain, is a fast-acting Fentanyl
formulation delivered using the Company's Taifun(R) dry powder
inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, and growth hormone deficiencies. LAB Research is a profitable
and growing contract research services division supporting its client
base from state-of-the-art facilities in Canada, the US, Hungary and
Denmark.
LAB's common shares trade on The Toronto Stock Exchange ("TSX")
under the symbol "LAB", on the Frankfurt Regulated Unofficial Market
under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with
51.3 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of LAB International
Inc. with respect to its performance, business and future events.
Such statements are subject to a number of risks, uncertainties and
assumptions. Actual results and events may vary significantly.
www.labinc.ca

Contact:

For further information: www.labinc.ca; Luc Mainville, Chief
Operating
Officer, +1-(450)-973-2240 ext. 1206, Fax: +1-(450)-973-2259,
mainvillel@labinc.ca; Frédéric Dumais, Director, Communication and
Investor
Relations, +1-(450)-973-2240 ext. 1207, Fax: +1-(450)-973-2259,
dumaisf@labinc.ca; James Smith, Investor Relations, +1-(416)-815-0700
ext.
229, Fax: +1-(416)-815-0080, jsmith@equicomgroup.com

Weitere Storys: LAB International Inc
Weitere Storys: LAB International Inc
  • 09.12.2004 – 15:58

    LAB International Shares Trading on the Frankfurt Stock Exchange

    Laval, Quebec (ots/PRNewswire) - LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE), an integrated drug development company focused on the inhalation market, today announced that its shares are available for trading on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange and on XETRA(R), the Deutsche Borse AG electronic trading system. The inclusion of LAB's securities in the ...

  • 06.12.2004 – 18:16

    LAB International to Initiate Phase II Trial for GHRH

    Laval, Canada (ots/PRNewswire) - - Malnutrition in Patients With Late Pre-end-stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. (TSX: LAB), an integrated drug development company focused on the inhalation market, today announced that, after completion of a successful dose-response trial, it has selected the first clinical indication for which it intends to evaluate ...